Galera Q1 net loss $15.4M; plans avasopasem NDA by end 2022

Galera Therapeutics, Inc.

2023-Q1 EPS reported -$0.58 vs consensus -$0.39 ▼ miss (-48.8%)

Net loss $(15.4M) ($0.58/share) vs $(18.7M) ($0.75) in Q1 2021; cash $60.9M funds into H2 2023.
Plans to submit NDA for avasopasem for severe oral mucositis by end of 2022 after FDA discussions.
Phase 3 ROMAN data accepted for oral presentation at 2022 ASCO; positive Phase 2a AESOP data reported.
R&D expenses $8.1M (down from $12.4M); G&A expenses $5.0M (flat).
Enrollment ongoing in Phase 2b GRECO-2 trial of rucosopasem for pancreatic cancer and Phase 1/2 GRECO-1 for NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.